Moderna has confirmed that a new analysis of its late-stage clinical trial for its coronavirus vaccine found a higher rate of infection in people who received doses early in the study.
According to Arabiya Net, the study examined cases in which people vaccinated in the company's experience were still infected with the Corona virus with the spread of the delta variant.
In Moderna's trial, first-time placebo subjects got the vaccine starting in December, after positive initial efficacy results were reported, creating a group She was vaccinated an average of five months later than those who had received the vaccine since the start of the study.
The company said it found that people who were vaccinated earlier had a 50% higher infection rate during July and August, compared to those who were vaccinated later. .
Moderna has asked the US Food and Drug Administration to authorize a third dose, a booster with half the dose of its current vaccine.
The increased risk of infection in this analysis quantifies the effect of immunodeficiency in the study,' Moderna said in a statement. This adds to the evidence for the potential benefit of a booster dose.
It is not clear when the Food and Drug Administration will make a decision on implementing the booster doses of Moderna's vaccine. Agency advisers are scheduled to study a potential boost to Pfizer and Piontech's coronavirus vaccine, which uses similar technology, on Friday.
